Cobblestone Capital Advisors LLC NY lifted its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 8.7% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 18,953 shares of the biopharmaceutical company’s stock after purchasing an additional 1,517 shares during the quarter. Cobblestone Capital Advisors LLC NY’s holdings in Bristol-Myers Squibb were worth $904,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc raised its position in Bristol-Myers Squibb by 1.0% during the 3rd quarter. Vanguard Group Inc now owns 128,376,159 shares of the biopharmaceutical company’s stock worth $7,969,593,000 after purchasing an additional 1,229,553 shares during the last quarter. BlackRock Inc. raised its position in shares of Bristol-Myers Squibb by 0.9% in the 4th quarter. BlackRock Inc. now owns 115,573,078 shares of the biopharmaceutical company’s stock worth $6,007,489,000 after acquiring an additional 999,193 shares in the last quarter. Northern Trust Corp raised its position in shares of Bristol-Myers Squibb by 4.4% in the 4th quarter. Northern Trust Corp now owns 22,576,884 shares of the biopharmaceutical company’s stock worth $1,173,547,000 after acquiring an additional 954,877 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Bristol-Myers Squibb by 1.1% in the 4th quarter. Bank of New York Mellon Corp now owns 17,303,884 shares of the biopharmaceutical company’s stock worth $899,456,000 after acquiring an additional 180,711 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Bristol-Myers Squibb in the 4th quarter worth about $797,038,000. Institutional investors and hedge funds own 77.65% of the company’s stock.
In related news, insider Karen Murphy Santiago sold 3,065 shares of the company’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $47.56, for a total value of $145,771.40. Following the completion of the transaction, the insider now directly owns 3,066 shares in the company, valued at $145,818.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Theodore R. Samuels II bought 5,000 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The stock was bought at an average price of $47.29 per share, with a total value of $236,450.00. Following the completion of the transaction, the director now directly owns 27,000 shares of the company’s stock, valued at approximately $1,276,830. The disclosure for this purchase can be found here. Insiders own 0.12% of the company’s stock.
BMY has been the subject of several research analyst reports. Credit Suisse Group reissued a “hold” rating and issued a $59.00 price objective on shares of Bristol-Myers Squibb in a research report on Friday, February 15th. BMO Capital Markets reissued a “buy” rating and issued a $59.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, February 19th. Bank of America lowered their price objective on Bristol-Myers Squibb from $53.00 to $51.00 and set a “neutral” rating for the company in a research report on Tuesday, February 19th. Zacks Investment Research lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Friday, February 22nd. Finally, ValuEngine lowered Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research report on Thursday, April 4th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the stock. Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus price target of $56.69.
BMY stock opened at $46.87 on Wednesday. The stock has a market cap of $76.47 billion, a price-to-earnings ratio of 11.78, a P/E/G ratio of 2.19 and a beta of 0.74. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.93 and a quick ratio of 1.79. Bristol-Myers Squibb Co has a 52-week low of $44.30 and a 52-week high of $63.69.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported $1.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.01. Bristol-Myers Squibb had a return on equity of 48.72% and a net margin of 22.23%. The business had revenue of $5.92 billion during the quarter, compared to the consensus estimate of $5.72 billion. During the same quarter in the previous year, the business earned $0.94 EPS. The company’s quarterly revenue was up 14.0% on a year-over-year basis. On average, analysts forecast that Bristol-Myers Squibb Co will post 4.18 EPS for the current year.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Read More: Forex
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.